We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Two MicroRNAs Are Linked to Lung Cancer

By HospiMedica staff writers
Posted on 27 Mar 2006
A new study shows that the expression pattern of certain microRNAs (miRNAs) is predictive of tumor aggressiveness in some patients with lung cancer. More...


These miRNAs are small segments of genetic material called ribonucleic acid (RNA), whose actions can change the expression of cancer-related genes within a cell and lead to malignancies. A team of researchers identified two miRNAs, "has-mir-155” and "has-let-7a-2” that could be used as prognostic indicators in patients with adenocarcinoma, a malignancy of the mucous glands in the lung. The study was the result of a collaboration among researchers at the Ohio State University Comprehensive Cancer Center (Columbus, Ohio, USA), the Jikei University School of Medicine (Tokyo, Japan), and the Center for Cancer Research at the U.S. National Cancer Institute (NCI, Bethesda, MD, USA). The results of the study appear in the March 2006 issue of the journal "Cancer Cell.”

High levels of "has-mir-155” or low levels of "has-let-7a-2” were associated with poor prognosis in the lung cancer patients. Overexpression of "has-mir-155” or the signaling of the miRNA to change the amount of a protein produced was the most significant indicator of this prognosis, independent of tumor stage. These miRNAs have been identified in other cancers but this is the first time”has-mir-155” has been linked to lung cancer.

Dr. Curtis Harris, chief of the laboratory of human carcinogenesis at NCI and co-leader of the study, noted that "in the future we can use miRNAs and other biological predictors to select patients who may need more-aggressive therapy.” He believes that miRNAs are going to be important biomarkers of not only diagnosis and prognosis, but therapy, as well. However, further testing will be required before these markers can be used for predicting patient outcomes.



Related Links:
Ohio State U. Comprehensive Cancer Center
Jikei University School of Medicine
NCI

New
Gold Member
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Resorbable Bovine Collagen Membrane
GenDerm
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.